Stockreport

Johnson & Johnson's nipocalimab shows promise in Sjögren's disease trial [Yahoo! Finance]

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF DAHLIAS is a randomised, multicentre, placebo-controlled, double-blind dose-ranging study that evaluated the effects of nipocalimab in adults with primary SjD, a chroni [Read more]